{
    "nctId": "NCT04059003",
    "briefTitle": "CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer",
    "officialTitle": "Circulating Tumor Cell Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: a Cohort Trial",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Efficacy of neoadjuvant chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* triple-negative breast cancer confirmed by breast biopsy;\n* stage III breast cancer (IIIA-C) assessed by CT or MRI;\n* neoadjuvant chemotherapy;\n* informed consent of patients and their family members.\n\nExclusion Criteria:\n\n* use of second-line chemotherapy regimen;\n* bilateral breast cancer;\n* inflammatory breast cancer;\n* pregnant or breast-feeding;\n* distant metastasis;\n* a history of other cancers or chest radiotherapy;\n* a history of abnormal blood test or other infectious symptoms.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}